LENZ Therapeutics (NASDAQ:LENZ) Issues Earnings Results, Misses Expectations By $0.25 EPS

LENZ Therapeutics (NASDAQ:LENZ) issued its quarterly earnings results on Tuesday. The company reported ($1.16) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.25), FiscalAI reports. The company had revenue of $1.59 million for the quarter, compared to the consensus estimate of $3.09 million.

Here are the key takeaways from LENZ Therapeutics’ conference call:

• Product performs in the real world: Company reports LNZ100 (VIZZ) produces near-vision improvement within ~30 minutes and up to ~10 hours, with early patient feedback and clinical results translating into encouraging persistence.
• Early commercial traction: the company estimates >45,000 monthly packs sold and >10,000 prescribing eye‑care professionals, and says its top 1,000 prescribers are writing ~40% more scripts per doctor vs. a comparable point in the Vuity launch.
• Sampling-driven launch strategy is producing a stickier refill base but a more gradual ramp in new patient starts, so broader adoption depends on physician education and time to build the category.
• Commercial scale-up underway: sales force expanding from 88 to 117 reps and a national DTC campaign (Sarah Jessica Parker spokesperson) is driving website traffic ~5x baseline (up to 10x on activations), with the company expecting DTC effects on scripts to materialize over ~two quarters.
• Financial and regulatory runway: LENZ exited the quarter with approximately $292.3M cash, is debt‑free, reported Q4 product revenue of ~$1.6M and ~ $32M quarterly cash burn, plans to allocate ~75–80% of OpEx to sales & marketing, and is pursuing multiple ex‑U.S. filings with potential approvals in 2027.

LENZ Therapeutics Trading Down 17.9%

LENZ traded down $1.97 on Tuesday, hitting $9.03. 3,911,787 shares of the company’s stock were exchanged, compared to its average volume of 1,037,837. LENZ Therapeutics has a fifty-two week low of $8.85 and a fifty-two week high of $50.40. The stock has a market cap of $282.55 million, a price-to-earnings ratio of -4.28 and a beta of 0.52. The firm has a 50-day moving average price of $14.48 and a 200-day moving average price of $24.74.

Hedge Funds Weigh In On LENZ Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC grew its stake in shares of LENZ Therapeutics by 51.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company’s stock valued at $41,000 after buying an additional 477 shares during the period. Quarry LP purchased a new stake in shares of LENZ Therapeutics during the 3rd quarter valued at approximately $27,000. JPMorgan Chase & Co. lifted its holdings in LENZ Therapeutics by 8.3% in the third quarter. JPMorgan Chase & Co. now owns 11,222 shares of the company’s stock valued at $523,000 after acquiring an additional 861 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in LENZ Therapeutics by 93.7% in the second quarter. BNP Paribas Financial Markets now owns 1,951 shares of the company’s stock valued at $57,000 after acquiring an additional 944 shares during the last quarter. Finally, Osaic Holdings Inc. grew its position in LENZ Therapeutics by 2,146.2% in the second quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock worth $34,000 after acquiring an additional 1,116 shares during the period. 54.32% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on LENZ. William Blair reiterated an “outperform” rating on shares of LENZ Therapeutics in a research report on Tuesday, March 10th. Wall Street Zen downgraded shares of LENZ Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. HC Wainwright reaffirmed a “buy” rating on shares of LENZ Therapeutics in a research note on Monday, December 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of LENZ Therapeutics in a report on Thursday, January 22nd. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $55.50.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.